Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             146 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Author index 1998
 34 S1 p. S43-
1 p.
 artikel
2 P30 A different P53 genotype predicts major response to antracycline or paclitaxel based neoadjuvant therapy in breast cancer Kandioler-Eckersberger, D.
 1998
 34 S1 p. S21-
1 p.
 artikel
3 P68 Adjuvant chemotherapy of patients with primary breast cancer (PABC) by fluorouracil (5-FU) Hazova, T.V.
 1998
 34 S1 p. S32-
1 p.
 artikel
4 P88 Adjuvant chemotherapy of primary breast cancer: 20 years follow up Gad-El-Mawla, N.
 1998
 34 S1 p. S37-
1 p.
 artikel
5 P104 Adjuvant chemotherapy plus alternated hormonal therapy (AVCF-TM) for HR+ N+ breast cancer: 13-year results of a randomized phase III trial Di Palma, M.
 1998
 34 S1 p. S40-S41
2 p.
 artikel
6 P16 Adjuvant Goserelin depot in premenopausal women with early breast cancer: Ovarian function, bone mineral density and survival. Preliminary data De Matteis, A.
 1998
 34 S1 p. S18-
1 p.
 artikel
7 P102 Adjuvant high-dose medroxyprogesterone acetate (HD-MPA) for early breast cancer. 13 years update of a multicenter randomized trial Focan, C.
 1998
 34 S1 p. S40-
1 p.
 artikel
8 P60 Adjuvant radiotherapy has no benefit after primary breast cancer treatment in selected postmenopausal patients Gruenberger, Th.
 1998
 34 S1 p. S31-
1 p.
 artikel
9 P14 Adjuvant tamoxifen treatment in breast cancer induces no activation of blood coagulation Oberhoff, C.
 1998
 34 S1 p. S18-
1 p.
 artikel
10 P87 Adjuvant therapy of primary breast cancer with doxorubicin vs. pirarubicin in combination with cyclophosphamide and 5-fluorouracil (FAC vs. FPC) Budišic, Z.
 1998
 34 S1 p. S36-S37
2 p.
 artikel
11 P52 Aesthetic results of the breast cancer conservative treatment in the lower quadrants Calabrese, C.
 1998
 34 S1 p. S26-
1 p.
 artikel
12 P44 Age is not a prognostic factor in breast cancer patients with combined losses of heterozygosity (LOH) in BRCA1 and BRCA2 regions Silva, J.M.
 1998
 34 S1 p. S24-
1 p.
 artikel
13 P106 A lack of evidence for the genotoxicity of tamoxifen and toremifene in the human endometrium Carmichael, P.L.
 1998
 34 S1 p. S41-
1 p.
 artikel
14 P33 Apoptosis and related proteins in ductal breast carcinoma Makar, A.
 1998
 34 S1 p. S22-
1 p.
 artikel
15 P100 ‘Arimidex’ (anastrozole): Lack of interactions with tamoxifen, antipyrine, cimetidine and warfarin Dowsett, M.
 1998
 34 S1 p. S39-S40
2 p.
 artikel
16 P99 Arimidex, tamoxifen alone or in combination (ATAC) adjuvant trial in post-menopausal breast cancer Baum, M.
 1998
 34 S1 p. S39-
1 p.
 artikel
17 P108 Assessement of changes in life quality of breast cancer patients under adjuvant CMF-chemotherapy by means of the EORTC QLQ-C30 Rensing, K.
 1998
 34 S1 p. S41-S42
2 p.
 artikel
18 P15 Blood coagulation and fibrinolysis after oral or intravenous cyclophosphamide containing adjuvant CMF-chemotherapy Oberhoff, C.
 1998
 34 S1 p. S18-
1 p.
 artikel
19 P7 BRCA1 and BRCA2 germline mutations in early-onset breast carcinoma patients Conti, A.R.
 1998
 34 S1 p. S16-
1 p.
 artikel
20 P67 Breast cancer: External beam radiotherapy and interstitial implantation — 10-year clinical results Hammer, J.
 1998
 34 S1 p. S32-
1 p.
 artikel
21 P36 CIP-1 protein expression in node-positive breast cancer patients Hupperets, P.
 1998
 34 S1 p. S22-S23
2 p.
 artikel
22 P82 Comparison of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF-chemotherapy versus tamoxifen in node positve breast cancer. An up-date of the German adjuvant breast cancer group (GABG) trial Kaufmann, I.M.
 1998
 34 S1 p. S35-
1 p.
 artikel
23 P2 Cost of adjuvant chemotherapy (CT) with CMF and tamoxifen in breast cancer (BC) Abdyldaev, R.A.
 1998
 34 S1 p. S15-
1 p.
 artikel
24 P28 Determination of c-erbB-2 protein in sera from primary breast cancer patients Imoto, S.
 1998
 34 S1 p. S21-
1 p.
 artikel
25 P90 Does the mobilization regimen influence peripheral blood stem cell (PBSC) tumor contamination in early breast cancer patients that undergo high dose chemotherapy? A comparison of chemotherapy plus G-CSF vs G-CSF mobilized PBSC Peccatori, F.
 1998
 34 S1 p. S37-
1 p.
 artikel
26 P83 Dose effect of epirubicin in amenorrhea induced by chemotherapy for breast cancer Weber, B.
 1998
 34 S1 p. S35-S36
2 p.
 artikel
27 P50 Effectiveness of postoperative radiotherapy in controling subclinical locoregional disease in breast cancer patients with positive axillary nodes Korzeniowski, S.
 1998
 34 S1 p. S25-S26
2 p.
 artikel
28 P97 Endometrial cancer and endometrial hyperplasia in postmenopausal women with breast cancer Montzka, P.
 1998
 34 S1 p. S39-
1 p.
 artikel
29 P1 Epidemiology and adjuvant therapy in early breat cancer: A prospective randomised study of 300 Indian patients Behgal, K.S.
 1998
 34 S1 p. S15-
1 p.
 artikel
30 P86 Epirubicin as a single agent in comparison to CMF in adjuvant therapy of stage I and II breast cancer Colozza, M.
 1998
 34 S1 p. S36-
1 p.
 artikel
31 P71 Epirubicin (EPI) and vinorelbine (VNR): A new promising combination for primary systemic chemotherapy for breast cancer Nisticò, C.
 1998
 34 S1 p. S33-
1 p.
 artikel
32 P43 Evaluation of bone marrow micrometastases as potential surrogate marker for efficacy of adjuvant treatment Braun, S.
 1998
 34 S1 p. S24-
1 p.
 artikel
33 P26 Evaluation of breast cancer utilizing proton magnetic resonance spectroscopy (MRS) Julka, P.K.
 1998
 34 S1 p. S20-
1 p.
 artikel
34 P74 Evaluation of clinical response to neoadjuvant chemotherapy of large primary breast tumours (≥3.5 CM) and correlation with magnetic resonance imaging Cocquyt, V.
 1998
 34 S1 p. S34-
1 p.
 artikel
35 P35 Expression of hepatocyte growth factor/scatter factor in primary breast cancer Venizelos, B.
 1998
 34 S1 p. S22-
1 p.
 artikel
36 P20 Extensive screening of women with high risk node positive breast cancer: An update Crump, M.
 1998
 34 S1 p. S19-
1 p.
 artikel
37 P85 Feasibility of docetaxel (D)-containing regimens in the adjuvant treatment (AT) of breast cancer (BC) Di Leo, A.
 1998
 34 S1 p. S36-
1 p.
 artikel
38 P56 First experience with the advanced breast biopsy instrumentation. A new system for stereotactic excisions of suspicious non-palpable breast lesions Zuber, M.
 1998
 34 S1 p. S27-
1 p.
 artikel
39 P93 Gene replacement used as adjuvant therapy in primary chemoresistant adenocarcinoma of the breast Giannios, J.
 1998
 34 S1 p. S38-
1 p.
 artikel
40 P91 High-dose chemotherapy with stem cell support in breast cancer: Does cyclophosphamide alter high-dose thiotepa pharmacokinetics? Dobrovolskaja, A.
 1998
 34 S1 p. S37-
1 p.
 artikel
41 P84 High dose epirubicin and cyclophosphamide (EC) vs cyclophosphamide, methotrexate, fluorouracil (CMF) as adjuvant chemotherapy in high risk premenopausal breast cancer patients (PTS). A prospective randomized trial Galligioni, E.
 1998
 34 S1 p. S36-
1 p.
 artikel
42 P8 High rate of one specific haplotype in the 13q12–13 region in breast cancer Silva, J.M.
 1998
 34 S1 p. S16-
1 p.
 artikel
43 P21 High-risk breast cancer patients (>9 involved nodes) M0 at conventional staging procedures: Additional findings suggesting M1-status Mohrmann, S.
 1998
 34 S1 p. S19-
1 p.
 artikel
44 P9 High risk breast/ovarian cancer families: Genetic counselling, testing and early cancer detection program Beckmann, M.W.
 1998
 34 S1 p. S16-S17
2 p.
 artikel
45 P38 Immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in node negative (N0) breast cancer (BC) Gerber, B.
 1998
 34 S1 p. S23-
1 p.
 artikel
46 P66 Inflammatory breast cancer: Chemotherapy and concommittant radiotherapy Tubiana-Mathieu, N.
 1998
 34 S1 p. S32-
1 p.
 artikel
47 P62 Influence of radiotherapy on the dose intensity of CMF as adjuvant treatment Escobedo, A.
 1998
 34 S1 p. S31-
1 p.
 artikel
48 P105 Inhibition of Tamoxifen's therapeutic benefit by Tangeretin in mammary cancer Depypere, H.T.
 1998
 34 S1 p. S41-
1 p.
 artikel
49 P64 Initial versus delayed radiotherapy combined with continuous 5-fluorouracile (F), cyclophosphamide (C) and doxorubicine (A) in inflammatory breast cancer (IBC) Palangie, T.
 1998
 34 S1 p. S32-
1 p.
 artikel
50 P12 In vitro cultivation of human mammary epithelial cancer cells. Study of their phenotypic characteristics and biologic behavior Saxena, S.
 1998
 34 S1 p. S17-
1 p.
 artikel
51 P13 Involvement of plasminogen activator inhibitor PAI-1 in in vitro growth of human breast cancer cell lines Prifti, S.
 1998
 34 S1 p. S17-S18
2 p.
 artikel
52 P53 Is axillary lymph node dissection indicated for early stage breast cancer? A decision analysis Prosnitz, L.R.
 1998
 34 S1 p. S26-
1 p.
 artikel
53 P51 Lack of correlation between menstrual phase during operation and prognosis of premenopausal patients with early breast cancer in a randomized study of adjuvant chemo-endocrine therapy Nomura, Y.
 1998
 34 S1 p. S26-
1 p.
 artikel
54 P47 Locally advanced breast cancer (LABC): Prognostic variables affecting results Baldini, E.
 1998
 34 S1 p. S25-
1 p.
 artikel
55 P95 Long-term intraarterial chemotherapy for breast cancer Yugrinov, O.G.
 1998
 34 S1 p. S38-
1 p.
 artikel
56 P11 Loss of retinoic acid receptor β expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer Widschwendter, M.
 1998
 34 S1 p. S17-
1 p.
 artikel
57 P92 Low morbidity and no mortality of high-dose cyclophosphamide, thiotepa and mitoxantrone plus autologous peripheral blood stem cell support for high-risk breast cancer patients Kröger, N.
 1998
 34 S1 p. S38-
1 p.
 artikel
58 P72 Meta-analysis of dose intensity in breast cancer neoadjuvant chemotherapy (1985–1997) Shparyk, Y.
 1998
 34 S1 p. S33-
1 p.
 artikel
59 P55 Minimally invasive surgery in wire-guided breast biopsy: Role of specimen mammography in predicting margins Sheridan, C.P.
 1998
 34 S1 p. S27-
1 p.
 artikel
60 P23 Monitoring the efficacy of primary chemotherapy for breast cancer using breast scintigraphy and immunocytochemical bone marrow screening Sommer, H.
 1998
 34 S1 p. S20-
1 p.
 artikel
61 P76 Multimodality therapy of 128 patients with locally advanced breast cancer in the era of mammography screening using standard FEC-prognostic and therapeutic implications Karlsson, Y.
 1998
 34 S1 p. S34-
1 p.
 artikel
62 P10 Multistep carcinogenesis of sporadic breast cancer Schnürch, H.G.
 1998
 34 S1 p. S17-
1 p.
 artikel
63 P37 Multivariate prognostic index with emphasis on proliferation adds specificity to standard prognostic factors in operable breast cancer Huovinen, R.
 1998
 34 S1 p. S23-
1 p.
 artikel
64 P80 Neoadjuvant chemotherapy in locally-advanced breast cancer: A preliminary report Baltalı, E.
 1998
 34 S1 p. S35-
1 p.
 artikel
65 P75 Neoadjuvant chemotherapy with paclitaxel (P) in breast cancer, T 3/4, N+ M0 Botto, H.G.
 1998
 34 S1 p. S34-
1 p.
 artikel
66 P73 Neoadjuvant therapy in stage II with T≥4CM and stage III breast cancer Enomoto, K.
 1998
 34 S1 p. S33-
1 p.
 artikel
67 P63 Neutron therapy in treating patients with breast cancer Slonimskaya, E.M.
 1998
 34 S1 p. S31-
1 p.
 artikel
68 P4 Ought the impact of different types of consumer involvement in various research activities (commissioning, trial protocol planning, Cochrane research reviews, etc.) be evaluated? Thornton, H.
 1998
 34 S1 p. S15-
1 p.
 artikel
69 P18 Plasma lipids and lipoproteins in breast cancer women in relation to body mass index (BMI) and fat distribution (WHR) Dziewulska-Bokiniec, A.
 1998
 34 S1 p. S19-
1 p.
 artikel
70 P49 Predictive parameters of response in primary CMF chemotherapy of breast cancer Escobedo, A.
 1998
 34 S1 p. S25-
1 p.
 artikel
71 P98 Preliminary report; Zoladex and tamoxifen as adjuvant treatment in premenopausal breast cancer Houghton, J.
 1998
 34 S1 p. S39-
1 p.
 artikel
72 P78 Primary chemotherapy in conservative treatment of stage II breast cancer patients Ostapenko, V.
 1998
 34 S1 p. S34-
1 p.
 artikel
73 P40 Prognostic factors predictive of lymph node status in breast cancer Distante, V.
 1998
 34 S1 p. S23-
1 p.
 artikel
74 P32 Prognostic parameters in node negative breast cancer receiving adjuvant CMF: Analysis of a randomized trial with emphasis on p53 and HER 2 neu Hardy-Bessard, A.C.
 1998
 34 S1 p. S22-
1 p.
 artikel
75 P42 Prognostic significance of mutant p53 in breast cancer patients Castiglione, F.
 1998
 34 S1 p. S24-
1 p.
 artikel
76 P31 Prognostic significance of vascular tumor emboli in 1518 breast carcinoma patients with small tumor size (≤3 cm) Pierga, J.-Y.
 1998
 34 S1 p. S21-
1 p.
 artikel
77 P48 Prognostic value of estrogen receptor (ER) status in breast cancer patients with five or more axillary lymph nodes (LN) involved Estévez, L.
 1998
 34 S1 p. S25-
1 p.
 artikel
78 P39 Prognostic value of plasminogenaktivator inhibitor type 1 and 2 in primary breast cancer Fersis, N.
 1998
 34 S1 p. S23-
1 p.
 artikel
79 P34 Prognostic value of vascular endothelial growth factor protein in node-negative breast cancer Linderholm, B.
 1998
 34 S1 p. S22-
1 p.
 artikel
80 P58 Prospective risk adapted therapy of ductal in situ breast cancer Buehner, M.
 1998
 34 S1 p. S27-
1 p.
 artikel
81 P65 Radiotherapy and concomitant chemo or ormonotherapy in early stage breast cancer: Acute and late local toxicity Valli, M.C.
 1998
 34 S1 p. S32-
1 p.
 artikel
82 P101 Randomized trial of two versus four years of adjuvant tamoxifen (AT) for postmenopausal women with node positive breast cancer Gallén, M.
 1998
 34 S1 p. S40-
1 p.
 artikel
83 P96 Randomized trials to assess the effectivity of tamoxifen as adjuvant treatment in node-negative and receptor positive breast cancer. The Heidelberg II and GABG II trials von Minckwitz, G.
 1998
 34 S1 p. S39-
1 p.
 artikel
84 P89 Reduction of metastases in breast cancer patients by adjuvant bisphosphonate treatment Diel, I.J.
 1998
 34 S1 p. S37-
1 p.
 artikel
85 P57 Risk factors of local recurrence in women with ductal carcinoma in situ (DCIS) according to the treatment Auvray, H.
 1998
 34 S1 p. S27-
1 p.
 artikel
86 P22 Role of single photon emission tomography with 99mTc-MIBI in diagnosis of metastatic widespread in breast cancer Riannel, Ju.E.
 1998
 34 S1 p. S19-S20
2 p.
 artikel
87 P109 Scalp cooling system (Thairapy system) in the prevention of alopecia in adjuvant CMF chemotherapy for breast cancer Fried, G.
 1998
 34 S1 p. S42-
1 p.
 artikel
88 P24 Scintimammography & MR mammography in assessing palpable breast masses and recurrent tumour Fenlon, H.M.
 1998
 34 S1 p. S20-
1 p.
 artikel
89 P61 Sector resection with or without postoperative radiotherapy for sage I breast cancer. Long term results and definition of a subgroup not requiering radiotherapy Liljegren, G.
 1998
 34 S1 p. S31-
1 p.
 artikel
90 P54 Sentinel lymph node biopsy in breast cancer — Which tumors are suitable? Reuhl, Th.
 1998
 34 S1 p. S26-S27
2 p.
 artikel
91 P25 Tc-99m-sestamibi scintimammography for the evaluation of breast malignancies Pappo, I.
 1998
 34 S1 p. S20-
1 p.
 artikel
92 P6 The breast-cancer susceptibility genes association to epidermal growth factor receptor (EGFR) & to oncogenes Hakim, A.A.
 1998
 34 S1 p. S16-
1 p.
 artikel
93 P27 The determination of tissue polypeptide antigen (TPA) in follow-up of breast cancer Findeisen, R.
 1998
 34 S1 p. S20-S21
2 p.
 artikel
94 P3 The effect of medical information on womens opinion about breast cancer Tschurtschenthaler, G.
 1998
 34 S1 p. S15-
1 p.
 artikel
95 P69 The effect of preoperative irradiation therapy and adjuvant chemotherapy for clinical stage III breast cancer Mudénas, A.
 1998
 34 S1 p. S33-
1 p.
 artikel
96 P94 Therapeutic efficiency of DNA-conjugated doxorubicin in chemotherapy of advanced stages of primary breast cancer Melnikov, D.Y.
 1998
 34 S1 p. S38-
1 p.
 artikel
97 P110 The role of nurse counsellor support groups for women diagnosed with breast cancer at hunter breast screen Rees, B.
 1998
 34 S1 p. S42-
1 p.
 artikel
98 P107 The ‘ZEBRA’ study: ‘Zoladex’ (goserelin) vs CMF as adjuvant therapy in the management of node positive stage II breast cancer in pre/peri-menopausal women aged 50 years or less Jonat, W.
 1998
 34 S1 p. S41-
1 p.
 artikel
99 P79 Three new highly active cisplatin-containing combinations in locally-advanced (stage III) and locally-recurrent breast carcinoma. A phase II randomized study Bisagni, G.
 1998
 34 S1 p. S35-
1 p.
 artikel
100 P5 Time trends in systemic adjuvant treatment of early-stage node-negative breast cancer in Québec Hébert-Croteau, N.
 1998
 34 S1 p. S15-S16
2 p.
 artikel
101 P45 Tumorbiological factors (uPA, PAI-1) as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients Jänicke, F.
 1998
 34 S1 p. S24-S25
2 p.
 artikel
102 P29 Tumor proliferative activity evaluated with thymidine labelling index predicts response to adjuvant chemotherapy Pronzato, P.
 1998
 34 S1 p. S21-
1 p.
 artikel
103 P41 Urokinase plasminogen activator and cathepsin D in micrometastatic cells of patients with primary breast cancer Solomayer, E.-F.
 1998
 34 S1 p. S23-S24
2 p.
 artikel
104 P81 Using high doses of 5-fluorouracil in patients with breast cancer: 3-year results of the treatment Slonimskaya, E.M.
 1998
 34 S1 p. S35-
1 p.
 artikel
105 P19 Value of seric cholesterol in the prognosis and treatment of breast cancer Lazo, R.
 1998
 34 S1 p. S19-
1 p.
 artikel
106 P17 Weight gain associated with breast cancer adjuvant chemotherapy Fried, G.
 1998
 34 S1 p. S18-S19
2 p.
 artikel
107 P103 What threshold for adjuvant tamoxifen in older breast cancer patients? A decision analysis Extermann, M.
 1998
 34 S1 p. S40-
1 p.
 artikel
108 P77 7-Year follow-up results of preoperative CMFAV in complex treatment of patients with locally advanced breast cancer Letyagin, V.
 1998
 34 S1 p. S34-
1 p.
 artikel
109 P70 5-Year results of combined modality approach in locally advanced breast cancer (LABC). Analysis of prognostic factors Zambetti, M.
 1998
 34 S1 p. S33-
1 p.
 artikel
110 P46 15 year update of the naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erb-B2 expression and Tamoxifen efficacy Bianco, A.R.
 1998
 34 S1 p. S25-
1 p.
 artikel
111 S33 Anti angiogenesis therapy and strategies Harris, A.L.
 1998
 34 S1 p. S8-
1 p.
 artikel
112 S27 Aromatase inhibitors and their role in the adjuvant treatment strategy Coombes, R.C.
 1998
 34 S1 p. S7-
1 p.
 artikel
113 S9 Biology of breast cancer risk and prognosis Pollak, M.
 1998
 34 S1 p. S4-
1 p.
 artikel
114 S35 CEF versus CMF in premenopausal women — Recent update Levine, M.
 1998
 34 S1 p. S9-
1 p.
 artikel
115 S41 Clinical research around the world: IBCSG trials Coates, A.
 1998
 34 S1 p. S10-
1 p.
 artikel
116 S31 Continuous infusional chemotherapy as pre-operative and as adjuvant treatment in early breast cancer Smith, I.E.
 1998
 34 S1 p. S8-
1 p.
 artikel
117 S10 Determination of clinical utility of tumor markers: A tumor marker utility grading system Hayes, D.F.
 1998
 34 S1 p. S4-
1 p.
 artikel
118 S3 Diet and breast cancer: Lessons from experimental studies Snyderwine, E.G.
 1998
 34 S1 p. S3-
1 p.
 artikel
119 S34 Dose intensity and dose density Piccart, M.J.
 1998
 34 S1 p. S8-
1 p.
 artikel
120 S43 EORTC and big trials Piccart, M.J.
 1998
 34 S1 p. S10-S11
2 p.
 artikel
121 S7 Experimental pathology and breast cancer genetics: Looking at malignant and premalignant tissues using new technologies Osin, P.
 1998
 34 S1 p. S3-
1 p.
 artikel
122 S28 GNRH analogues and ovarian ablation: How to integrate in the adjuvant strategy Pritchard, K.I.
 1998
 34 S1 p. S7-
1 p.
 artikel
123 S24 How to combine radiation (RT) and systemic (ST) therapies Harris, J.R.
 1998
 34 S1 p. S6-
1 p.
 artikel
124 S14 Hypothesis and practice: Are there several types of treatment for DCIS? Silverstein, M.J.
 1998
 34 S1 p. S4-
1 p.
 artikel
125 S39 Impact of different adjuvant therapy strategies on quality of life (QOL) in breast cancer survivors (BCS) Ganz, P.A.
 1998
 34 S1 p. S9-S10
2 p.
 artikel
126 S20 Integration of plastic surgery in the course of breast cancer surgery to improve final cosmetic result and radicality of tumor excision Petit, J.-Y.
 1998
 34 S1 p. S5-
1 p.
 artikel
127 S22 Is primary chemotherapy useful in all patients? Scholl, S.
 1998
 34 S1 p. S6-
1 p.
 artikel
128 S36 New developments in high-dose chemotherapy for breast cancer Basser, Russel
 1998
 34 S1 p. S9-
1 p.
 artikel
129 S40 North American adjuvant breast cancer trials Abrams, J.S.
 1998
 34 S1 p. S10-
1 p.
 artikel
130 S25 Novel approaches using radiation techniques Rutqvist, Lars E.
 1998
 34 S1 p. S6-
1 p.
 artikel
131 S21 Preoperative therapy (PROP) for breast cancer Fisher, B.
 1998
 34 S1 p. S5-S6
2 p.
 artikel
132 S19 Pre-surgical chemotherapy Margolese, R.
 1998
 34 S1 p. S5-
1 p.
 artikel
133 S5 Prevention of breast cancer Costa, A.
 1998
 34 S1 p. S3-
1 p.
 artikel
134 S30 Putting the taxanes to work Gianni, L.
 1998
 34 S1 p. S7-S8
2 p.
 artikel
135 S29 Putting the taxanes to work: Open questions Conte, P.F.
 1998
 34 S1 p. S7-
1 p.
 artikel
136 S37 Quality of life assessment in the adjuvant setting: Is it relevant? Gelber, R.D.
 1998
 34 S1 p. S9-
1 p.
 artikel
137 S38 Quality of life measurements in the IBCSG: Past, present and future Hürny, Ch.
 1998
 34 S1 p. S9-
1 p.
 artikel
138 S44 Review of Italian breast cancer study group (GROCTA) trials Boccardo, F.
 1998
 34 S1 p. S11-
1 p.
 artikel
139 S46 Review on current trials of the German adjuvant breast cancer group (GABG) Kaufmann, M.
 1998
 34 S1 p. S11-
1 p.
 artikel
140 S42 Scandinavian/nordic adjuvant trials in breast cancer Mouridsen, H.T.
 1998
 34 S1 p. S10-
1 p.
 artikel
141 S15 Shifting knowledge on in situ carcinomas: The pathologist's view Schnitt, S.J.
 1998
 34 S1 p. S4-
1 p.
 artikel
142 S32 Tailored therapy to equal toxicity: Is it possible? Bergh, J.
 1998
 34 S1 p. S8-
1 p.
 artikel
143 S17 The axilla; To clear or not to clear? That is the question! Blichert-Toft, M.
 1998
 34 S1 p. S5-
1 p.
 artikel
144 S18 The axilla; To clear or not to clear? That is the question! Veronesi, U.
 1998
 34 S1 p. S5-
1 p.
 artikel
145 S1 The changing concepts in treating breast cancer Veronesi, U.
 1998
 34 S1 p. S3-
1 p.
 artikel
146 S26 The molecular biology of the estrogen receptor (ER) aids in the understanding of tamoxifen resistance and breast cancer prevention with raloxifene Jordan, V.C.
 1998
 34 S1 p. S6-S7
2 p.
 artikel
                             146 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland